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MK-2048. V54I, a previously unreported mutation, selected with raltegravir, was identiﬁed as a possible
compensation mutation. Mechanisms by which N155H, Q148H/K/R, Y143R and E92Q confer resistance are
proposed based on a structural model of integrase. These data improve the understanding of resistance
against raltegravir and cross-resistance to MK-2048 and other integrase inhibitors, which will aid in the
discovery of second-generation integrase inhibitors.A, Gen De Wittelaan L 11B 3,
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The human immunodeﬁciency virus (HIV) causes acquired
immunodeﬁciency syndrome (AIDS). Infection with HIV remains a
signiﬁcant burden on global human health, with an estimated 33.4
million people currently living with HIV and 2.7 million new
infections reported in 2008 (WHO. Aids epidemic update. 2009).
The viral enzymes reverse transcriptase, protease and integrase
(IN) are essential for the HIV replication cycle and are encoded by the
pol gene. HIV-1 IN, a 32 kDa enzyme (288 amino acids), comprises
three distinct functional domains. The N-terminal domain (amino
acids 1–50) is believed to be involved in protein multimerization and
contains anH-H-C-C zincﬁnger-likemotif,which coordinates zinc. The
catalytic core domain (amino acids 51–212) contains the catalytic
triad of acidic residues D64, D116 and E152 comprising a highly
conserved DD-35-E motif that likely coordinates two divalent metal
ions, probably magnesium, and is required for catalytic activity
(Asante-Appiah and Skalka, 1997; Esposito and Craigie, 1999). The
C-terminal domain (amino acids 213–288) has DNA-binding activity
and is therefore thought to play a role in binding to viral and host DNA.During the integration process, IN recognizes speciﬁc sequences in
the long terminal repeats (LTRs) of the viral genome and binds to the
viral DNA in preparation for catalytic activity. When DNA-bound, the
IN enzyme removes a GT dinucleotide, adjacent to a conserved 3′CA
sequence, from each viral cDNA 3′-end in a process termed 3′-
processing. The 3′-processed DNA product, as part of the pre-
integration-complex, is then trafﬁcked to the nucleus and imported
through the nuclear envelope for subsequent IN-facilitated strand
transfer into the cellular chromosomal DNA. Following strand
transfer, the gaps in the DNA are likely annealed by host DNA repair
enzymes, and the proviral DNA is establishedwithin the genomic DNA
of the infected cell (Asante-Appiah and Skalka, 1997; Engelman et al.,
1991; Esposito and Craigie, 1999).
With the possible exception of the V(d)J polynucleotide transferase
RAG1, there is no likely mammalian homologue for IN (Melek et al.,
2002). Also, IN is essential for viral infectivity (LaFemina et al., 1992;
Sakai et al., 1993) and the IN sequence in the pol gene is highly
conserved among HIV-1 clinical isolates (Cannon et al., 1994;
Ceccherini-Silberstein et al., 2009; Reinke et al., 2001). Therefore, IN
has remained an attractive target for antiretroviral therapy over the
last decade (Pommier et al., 2005; Witvrouw et al., 2004). Recent
progress has resulted in the IN inhibitors (INIs) elvitegravir (EVG)
and raltegravir (RAL), with EVG reaching late stage clinical trials (Sato
et al., 2006) and RAL approved for use in treatment-experienced
patients (Cahn and Sued, 2007; Grinsztejn et al., 2007) and very
Table 1
Overview of genotypes of the viruses found with the automated IVRS experiments in
96-well plates at a ﬁnal concentration of 6 µM RAL.
Passage Selected mutationsa Mutations post-reculturea
Virus 1 43 V54I E138K G140A
Q148R
V54I E138K G140A Q148R
Virus 2 38 E138K G140A Q148R E138K G140A Q148R
Virus 3 19 E138K G140A Q148K
S230R
E138K G140A Q148K S230R/S
D232D/N
Virus 4 51 L63I L74M A128T E138K
Q148R V151I
L63I L74M A128T E138K Q148R
V151I
Virus 5 33 L74M E92Q V151I N155H
E157Q
L74M E92Q V151I N155H E157Q
D232D/N V265A/V
Virus 6 19 E138E/K Q148R E138E/K Q148Q/R
a Sequencing results are reported as amino acid changes compared with HIV-1 (IIIB)
wild type reference sequence. Mutations present in more than 25% of the global virus
population were detected as a mixture with the wild-type virus.
Table 2
Overview genotypes of the viruses selected with MK-2048 or Cmpd G.
Selection with Passage Selected mutationsa
Virus 7 MK-2048 41 G140E/G
Virus 8 Cmpd G 41 no mutations selected
a Sequencing results are reported as amino acid changes compared with HIV-1
(HXB2D) wild type reference sequence. Mutations present in more than 25% of the
global virus population were detected as a mixture with the wild-type virus.
Fig. 1. Cross-resistance of six different RAL-selected HIV-1 strains. The viruses found in
the IVRS experiments with RAL were tested for susceptibility to RAL and other INIs.
Relative changes in susceptibility of the viruses compared with wild-type IIIB virus are
displayed on the graph.
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an effort to design novel second-generation INIs, a series of
compounds was optimized resulting in two INIs, MK-2048 and
compound G (Cmpd G), with improved resistance proﬁles compared
with the ﬁrst-generation INIs (Vacca et al., 2007).
The use of combinations of antiretroviral drugs in highly active
antiretroviral therapy (HAART) has proven remarkably effective in
controlling the progression of HIV disease and prolonging survival
(Palella et al., 1998; Richman, 2001), but the efﬁcacy of regimens can be
compromised by the development of resistance (DeGruttola et al., 2000;
Ledergerber et al., 1999; Richman, 2006). All approved antiretroviral
drugs have elicited resistance mutations, and the search for next-
generation inhibitors with increased efﬁcacy, superior resistance
proﬁles, higher genetic barriers to resistance development and
improved safety proﬁles in all classes of antiretrovirals, is a current
focus of the pharmaceutical industry and other research institutes.
Following clinical validation of IN as a target for antiretroviral
therapeutic intervention (DeJesus et al., 2006; Grinsztejn et al., 2007),
INIs are expected to become frequently used in HAART, and the
corresponding resistance mutations will result in a clear requirement
for second generation INIs to maintain the efﬁcacy of regimens
containing an INI component. Currently, emerging data from clinical
studies of RAL and EVG elucidate relationships between certain
mutations and the loss of efﬁcacy of INIs (Cooper et al., 2008; McColl
et al., 2007). In order to establish the requirements of a second
generation INI, many factors, including resistance proﬁle, genetic
barrier, safety proﬁle, dosing, and necessity for boosting must be
considered. A comprehensive understanding of the resistance proﬁle of
ﬁrst-generation INIs, the pathways employedby the virus to circumvent
inhibition, and the degree of cross-resistance to other INIswill therefore
enable evaluation of investigational compounds as potential second-
generation INIs.
RAL showed excellent therapeutic efﬁcacy in patients infected
with HIV-1, including treatment-naïve HIV-1-infected patients (Mar-
kowitz et al., 2006) and patients with multidrug-resistant HIV-1 and a
history of treatment failure (Grinsztejn et al., 2007; Steigbigel et al.,
2008). Resistance to RAL has been investigated in vitro (Kobayashi et
al., 2008;Wai et al., 2007) and in vivo (Charpentier et al., 2008; Cooper
et al., 2008; Malet et al., 2008). A resistant virus with genotype
E138A/G140A/Q148K was selected in vitro by Wai et al. (2007).
N155H and Q148K/R pathways with additional mutations were
reported by Kobayashi et al. (2008). However, virologic failure in
patients on RAL treatment was generally associated with a mutation
at one of the three residues Y143, Q148 or N155 (Cooper et al., 2008).
Other clinical studies highlighted the selection of additional minor
resistance mutations including E92Q, E92A/T66A and E157Q (Char-
pentier et al., 2008; Malet et al., 2008). Secondary mutations
described in the Q148H/K/R pathway include L74M+ E138A,
E138K, or G140S. Mutations associated with the N155H pathway
include L74M, E92Q, T97A, E92Q+T97A, Y143H, G163K/R, V151I, or
D232N. The Y143R/H/C mutation seems uncommon (Miller et al.,
2008).
Here, we report the results from a series of in-vitro resistance
selection (IVRS) experiments with RAL in parallel with MK-2048 and
Cmpd G, and the proﬁling of the selected and recombinant viruses
containing mutants from this and other resistance studies (Goethals
et al., 2008; Kobayashi et al., 2008) to delineate the contribution of
each mutation to the susceptibility to RAL, MK-2048, Cmpd G and a
panel of diverse INIs.
Results
Selection of HIV-1 strains resistant to RAL
A parallel IVRS methodology in 96-well plates (Goethals et al.,
2008) was used to select six strains with reduced susceptibility to RAL.The drug-resistant strains were selected by serial passage of HIV-1 IIIB
in the presence of increasing concentrations of RAL. When the viruses
were propagated at a ﬁnal concentration of 6 µM, a concentration 600
times higher than the EC50 of RAL, viruses were genotyped to identify
mutations. One selected strain required 19 passages to accumulate
mutations enabling replication in the presence of 6 µM RAL, where
other strains required 33, 38, 43 or 51 passages.
Six parallel IVRS experiments elucidating different resistance
pathways (Table 1) were performed. Viruses with primary mutations
Q148R, Q148K or N155H were selected. Four out of six viruses
selected the Q148Rmutation. A newmutation V54I was selected as an
additional mutation in a virus containing the Q148R mutation.
In parallel with RAL, viruses were propagated in the presence of
increasing concentrations of MK-2048 or Cmpd G (Table 2). After 41
passages, one virus was selected with 1.6 µM of MK-2048 and one
with 1 µM of Cmpd G. Although both viruses were propagated at a
concentration 500 times higher than the EC50 of their respective
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of a mutant and wildtype, i.e. G140E/G in virus 7, was observedwhich
was selected with 1.5 µM MK-2048.
Phenotypic (cross)-resistance of the RAL-selected HIV-1 strains to a
panel of INIs
All six RAL-selected HIV-1 strains were re-cultured and the
antiviral activity of RAL was determined. In parallel, the susceptibility
of the selected HIV strains to a panel of INIs, namely EVG, PACA, L-Fig. 2. Effect of site-directed mutants on the susceptibility of HIV-1 (HXB2D) for different INIs
type HIV-1 (HXB2D). Relative changes in susceptibility of the viruses to the different com
pathway (C) or the Q148K pathway (D). Missing bars in the graphs point to susceptibilitie870,810, PICA and two INIs with a second-generation resistance
proﬁle, MK-2048 and Cmpd G, was determined to establish the degree
of cross-resistance (Fig. 1). The re-cultured viruses were genotyped to
conﬁrm that mutations had been preserved throughout the re-
culturing process (Table 1). All primarymutations weremaintained in
the six selected viruses after reculture, except in virus 6, were the
Q148R mutation reverted to a mixture Q148Q/R.
In comparison with wild-type virus, viruses 1 to 5 showed large
reductions in susceptibility to RAL, EVG, PACA and L-870,810 (N240-
fold) (Fig. 1). Virus 6 (E138E/K Q148Q/R) was more susceptible. IN mutations were incorporated by site-directed mutagenesis in the backbone of wild-
pounds are shown with the single mutations (A), the Q148R pathway (B), the Q148H
s that are not measured.
Fig. 3. Replication kinetics of recombinant viruses. MT4 cells were infected with
recombinant viruses with mutations at the 148 locus, at an MOI of 0.0001. Cells were
evaluated microscopically for HIV-induced cytopathic effect, and viral p24 levels were
determined daily in cell-free supernatant. Experiments were performed in duplicate.
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11- and 65-fold) than viruses 1 to 5. Viruses 1 and 2, two viruses
harboring the primary mutation Q148R and additional mutations
G140A, E138K or V54I, showed greatly reduced susceptibility to MK-
2048 (370- and 140-fold, respectively), withmoremoderate reductions
in susceptibility to Cmpd G (85- and 25-fold, respectively). Virus 1
differs fromvirus 2byonly one extramutationV54I, but confers a higher
reduction in susceptibility to all INIs than virus 2, except to PACA,were a
similar reduction was observed. Virus 3 (E138K G140A Q148K S230R),
virus 4 (L63I L74MA128T E138KQ148RV151I), and virus 5 (L74ME92Q
V151I N155H E157Q) were 50 to 70-fold less susceptible to MK-2048
and 5- to 15-fold to Cmpd G. Virus 6 (E138E/K Q148Q/R) displayed
wild-type susceptibility to MK-2048 and Cmpd G. Viruses 1 to 5
conferred a 30-fold reduction in susceptibility to PICA, where virus 6
showed only 6-fold reduction in susceptibility to PICA (Fig. 1).
Effect of the site-directed mutants on the susceptibility of HIV-1
(HXB2D) to different INIs
Mutations selected in this study and reported in previous studies
from this lab and others, including clinical data (Cooper et al., 2008;
McColl et al., 2007), were incorporated in a wild-type HIV-1 backbone
(HXB2D) by site-directed mutagenesis, and susceptibility of the
resulting viruses to each INI was determined (Fig. 2). Speciﬁcally, the
Q148R, the Q148K and the N155H mutation, all with their additional
mutations selectedduring IVRS experiments, and the clinically observed
mutations N155S, T66I, Q148H, G140S, and Y143C were included.
Twenty-three combinations of single, double, triple or quadruple
mutations were tested for susceptibility to RAL and to other INIs
(Fig. 2). AZT, which was used as a control antiviral, showed EC50 values
for the INmutants that was consistentwith the EC50 for wild-type virus,
indicating full susceptibility to the reverse transcriptase inhibitor.
Small reductions (b6-fold) in virus susceptibility to EVG, RAL, or
any other INI used in this study was observed when the impact of a
singular V54I, L74M, A128T, E138K, G140A/S, V151I, E157Q or S230R
mutation was tested (Fig. 2A). The mutations G140A/S and E138K
have been previously observed accompanying one of the primary
resistance mutations Q148K/H/R and are considered as secondary
mutations (Nakahara et al., 2009).
The T66I mutation, while conferring 25-fold reduced susceptibility
to EVG, caused only 1- to 6-fold reduction in susceptibility to the other
INIs (Fig. 2A). Y143C, a resistance associated mutation (RAM) of RAL
(Cooper et al., 2008), conferred a 4-fold reduction in susceptibility to
RAL, but did not reduce susceptibility to the other tested INIs (b3-
fold). The single mutations E92Q, N155H/S and Q148K/R, which are
considered as RAMs of RAL or EVG (Cooper et al., 2008; McColl et al.,
2007), conferred low to moderately reduced susceptibility to RAL and
PICA (b14-fold) but moderately to highly reduced susceptibility to
EVG, PACA and L-870,810 (6- to 90-fold). Q148H confers a 6-fold
reduction in susceptibility to RAL and a 5-fold reduction to L-870,810
and PACA, but wildtype susceptibility to the other INIs. The mutations
Q148R and E92Q showed wild-type susceptibility to MK-2048 and
Cmpd G, while the mutation N155H conferred 6- and 4-fold reduced
susceptibility to respectively MK-2048 and Cmpd G (Fig. 2A).
Compared with the effect of Q148R and G140A on their own,
combining both mutations in a common backbone resulted in a large
decrease in susceptibility (7- to 564-fold) to the INI panel (Fig. 2B). The
triple mutant Q148R/G140A/E138K conferred similar reductions in
susceptibility as the double mutant Q148R/G140A to most of the
members of the INI panel, but led to a decreased susceptibility to Cmpd
G. Themutation V54I had no additional effect on virus susceptibility to
the tested INIs, when added to the triple mutant Q148R/G140A/
E138K.
The mutation Q148H on its own conferred between 1- and 6-fold
decreases in susceptibility to the panel of INIs, while addition of the
G140S mutation led to a further decrease in susceptibility between 3-and 1750-fold (Fig. 2C). Again, the mutation E138K had no additional
effect on HIV-susceptibility to the tested INIs.
The mutation Q148K conferred reduced susceptibility to all tested
INIs (6- to 90-fold). G140S or G140S/E138K, in combination with
Q148K, had no or only limited additional effect on the susceptibility to
most INIs (Fig. 2D). The double (Q148K/G140S) and triple mutant
virus (Q148K/G140S/E138K) did not confer reduced susceptibility to
MK-2048 and Cmpd G.
Replication kinetics of mutant HIV-1 viruses
To investigate the effect of the drug-induced mutations of virus 1
(Q148R/G140A/E138K/V54I) on viral replication, the corresponding
recombinant viruses were examined for their ability to replicate in
MT4 cells (Fig. 3). The recombinant virus with the single Q148R
mutation showed a small reduction in p24 production relative to the
replication of the wild-type HIV-1 HXB2D. Introducing the G140A on
top of Q148R, resulted in even lower replication rate. Introducing
E138K partly recovered this reduced replication efﬁciency of the
Q148R/G140A virus. Addition of the V54I mutation to the virus with
the mutations Q148R, G140A and E138K, resulted in a replication
capacity comparable with wildtype HXB2D virus.
Three-dimensional docking model of HIV-1 IN with RAL
RALwas docked into themodel of Chen et al. (2008) and it adopted
a binding mode, common to other potent inhibitors, sharing four key
elements (Fig. 4):
1) The inhibitor-binding site exists only upon 3′-processing of viral
DNA, removing a GT dinucleotide;
2) The hydrophobic tail (benzyl moiety) binds in a putative
hydrophobic pocket formed mostly by the ﬂexible active-site
loop (site 1);
3) The polar moiety chelates only the Mg2+ coordinated by D116 and
E152 (site 2), the other Mg2+ is shielded by IN and viral DNA and
therefore not accessible by the INI;
4) A polar interaction between the inhibitor and a triad motif
consisting of C65, H67 and E92 (site 3).
Fig. 4. Three-dimensional docking model of HIV-1 IN with RAL. This binding model is
based on the coordinates of a binding model of L-870,810 as described in Fig. 5a of Chen
et al. (2008). RAL (ball-and-stick representation) was docked into the model of Chen
et al. (2008). IN is shown as a gray surface. The catalytic triad residues (D64, D116 and
E152) are shown in blue and magnesium ions are in pink. The resistance-associated
mutations of RAL are shown in red. Viral DNA is represented with green (5′ end) and
yellow (3′ end) ball-and-sticks.
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Q148 and N155 were highlighted in the model. All residues clustered
proximal to the catalytic triad represented by the DDE-motif of IN.
Q148 and Y143 are located in the ﬂexible loop (site 1), where the
benzyl moiety of RAL is situated. The glutamic acid at position 92 is
located at site 3.
Discussion
Here we report the results from IVRS studies with RAL and the
effects of selected mutations on the virus susceptibility to RAL and on
cross-resistance to other ﬁrst-generation INIs and to the second-
generation INIs MK-2048 and Cmpd G. In parallel with the RAL IVRS
studies, resistance selection was performed with MK-2048 and
Cmpd G.
RAL failure is associated with INmutations in at least three distinct
genetic pathways deﬁned by two or more mutations including a
signature mutation at Q148H/K/R, N155H, or Y143R/H/C, and one or
more additional minor mutations (Cooper et al., 2008; Johnson et al.,
2008). The existence of several INI resistance pathways is similar to
what has been described for other antiretroviral classes, such as
nucleoside-, and non-nucleoside reverse transcriptase inhibitors or
protease inhibitors (Clavel and Hance, 2004). However, the determi-
nants of the evolution toward these different proﬁles are unknown.
They could be related to different factors such as naturally occurring
polymorphisms in IN (Lataillade et al., 2007), pharmacokinetic factors
such as RAL trough levels (Winslow et al., 1996), or sequences of other
proteins like reverse transcriptase, which may interact with IN (Wu
et al., 1999; Zhu et al., 2004).
Here, distinct resistance pathways were selected with RAL, i.e. the
Q148R, the Q148K and the N155H pathways. Some mutations may
develop less readily than others, for example, the substitution Y143R
requires at least two nucleotide changes (TAC to CGC), while the
substitution Q148R (CAA/G to CGA/G) requires only one nucleotide
change. This might explain why Y143R was not selected. Although
different mutations were selected with RAL, no mutations were
selected with MK-2048 or Cmpd G during the same time frame,
suggesting a potentially higher genetic barrier to resistance develop-ment and possible second-generation resistance proﬁles of the two
investigational compounds MK-2048 and Cmpd G.
When testing the RAL-selected viruses for susceptibility to a panel of
INIs, high-level cross-resistance betweenRAL, EVG, PACAand L-870,810
was observed. The similarity between the pharmacophores of these
compounds suggests a similar binding mode, which might explain the
similar changes in virus susceptibility to those compounds. Less cross-
resistance was observed between RAL and MK-2048, Cmpd G, or PICA,
where PICA has a different pharmacophore compared with RAL. The
pharmacophore of PICA is a pyrido hydroxamic acid moiety, while the
pharmacophore of RAL is a diketo amide. It is expected that both
pharmacophores share a similar binding mode at the catalytic triad,
albeit with small differences in their geometry. This variability in both
pharmacophores may explain the difference in susceptibility and the
difference in potency of the compounds. But although the change in
susceptibility compared with wild type of the most heavily mutated
viruseswas several times lower for PICA than for RAL, the lower potency
and higher toxicity of PICA likely precluded its further development.
Less cross-resistancewas also seen between RAL andMK-2048 or Cmpd
G in linewithprevious observations (Vacca et al., 2007;Wai et al., 2007),
highlighting their potential as second-generation INIs.
For the ﬁrst time, V54I is reported as a mutation selected by RAL in
vitro. Comparison of the two RAL-selected viruses, virus 1 (Q148R
G140A E138K V54I) and virus 2 (Q148R G140A E138K), differing from
each other only by the mutation V54I, showed that virus 1 conferred a
slightly higher reduction in susceptibility to all INIs, except PACA,
compared with virus 2, which does not harbor V54I.
To test the individual or the combined effect of the selected
mutations on viral susceptibility to the INI panel, single, double, triple
and quadruple mutations were constructed in a wild-type HIV-1
backbone via site-directed mutagenesis. In addition, the mutations
N155S, T66I, Q148H, G140S, Y143C selected by RAL (Cooper et al.,
2008) or EVG (McColl et al., 2007) in the clinic, were included in the
analysis.
The IN mutation T66I, previously identiﬁed as a resistance-
associated mutation of EVG (Goethals et al., 2008), has also been
selected in vitro with S-1360 (Fikkert et al., 2004), L-708,906 (Fikkert
et al., 2003) and L-731,988 (Hazuda et al., 2000), but is not considered
as a resistance mutation of RAL, as conﬁrmed in our study.
E92Qhas been previously selectedwith EVG (Goethals et al., 2008),
and is considered as a RAM for EVG. Hombrouck et al. (2008) selected
E92Q during IVRS studies with the naphthyridine L-870,810, and
Kobayashi et al. (2008) selected E92Q with EVG, S-1360 and L-
870,810. E92Qhas been associated occasionallywith failure in patients
on RAL treatment as an additional minor mutation of RAL accompa-
nying the primary N155H mutation (Johnson et al., 2008; Malet et al.,
2008). Therefore, it will be preferable for a second generation INI to
effectively inhibit the N155H/E92Q virus.
Mutation Y143C, although associated with virologic failure in
patients treated with RAL, was not selected by our IVRS studies with
RAL. Y143C seems to be exclusively associated with low level of
resistance to RAL, but remains uncommon.
Mutation N155S was previously selected in vitro by a diketo acid
analog (Hazuda et al., 2004) and by S-1360 (Kobayashi et al., 2008).
Only a 4-fold reduction in susceptibility to RAL was conferred by
N155S, where in comparison the N155H mutant showed a 12-fold
reduction in susceptibility to RAL. Thus, the change of the amino acid
at position 155 from a serine to a histidine would increase resistance
to RAL. The N155H mutation is one of the major pathways selected
with RAL or with EVG in vivo (Cooper et al., 2008; McColl et al., 2007).
Here we observe N155H as the only primary mutation that confers, as
a single mutation, a reduction in susceptibility to Cmpd G and MK-
2048, although the reduction is minor (4- and 6-fold respectively).
Another major pathway selected with RAL or EVG involves the
mutation of the glutamine at position 148 to a lysine, a histidine or an
arginine. Because Q148H is the most common mutation selected with
Fig. 5. Structure of seven distinct IN inhibitors used in this study. EVG (2) RAL (3) L-
870,810 (4) PACA (5) PICA (6) MK-2048 (7) Cmpd G. The essential pharmacophore of
these compounds is highlighted in red.
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generation compounds to inhibit the viruses with this mutation. We
observed that Q148H alone retained wild-type susceptibility to MK-
2048 and Cmpd G, highlighting their potential as second generation
inhibitors.
In our study, the additional effect of G140A in combination with
Q148R caused an additional decrease in susceptibility to the INIs and a
reduction in replication capacity compared with the recombinant
virus with the Q148R mutation alone.
Delelis et al. (2009) demonstrated that in the Q148H/G140Smutant
virus, the G140S rescued the replication deﬁciency of the Q148H
mutant, while the mutation Q148H is responsible for resistance to RAL.
Fransen et al. (2008) found that Q148H and G140S in combination
reduced susceptibility to RAL much more than either mutation alone.
We also observed a large decrease in susceptibility to all INIs due to the
additionofG140S toQ148Handwe speculate thatQ148H/G140Swould
evolve from the Q148H virus, due to both a recovery of replicative
capacity and a decrease in susceptibility. G140S in combinationwith the
Q148K mutation had only a limited additional effect on the suscepti-
bility to most INIs. Fransen et al. (2008) even observed a suppressed
resistance conferred by Q148K and G140S together compared with
Q148K alone. Nakahara et al. (2009) have reported an additional 2-fold
increase in susceptibility to S-1360when adding the G140Smutation to
Q148K. Moreover, a reduced viral ﬁtness of the Q148K virus compared
with wild-type virus was reported, where the ﬁtness was partially
recovered by addition of the secondary mutation G140S to Q148K. The
addition of E138K to the mutant viruses Q148K/G140S, Q148H/G140S
or Q148R/G140A did not confer increased resistance against the INIs,
but E138K did partly compensate the reduced replication of themutant
virus Q148R/G140A.
The addition of V54I to the Q148R/G140A/E138K recombinant
virus did not confer further resistance to RAL or to the other INIs, but
slightly improved the replication capacity of the triple mutant virus.
To our knowledge, V54I has not been identiﬁed as a polymorphism
(Lataillade et al., 2007) and due to the better replication capacity of
the recombinant virus with V54I, we suggest it is a compensatory
mutation resulting from IVRS with RAL.
To better understand the inﬂuence of the found mutations on
inhibitory activity, RAL was docked into the model of Chen et al.
(2008). The mutations, associated with resistance to RAL, i.e. E92Q
Y143R/C, Q148R/H/C and N155S/H are highlighted in the model. All
primary mutations clustered proximal to the catalytic triad repre-
sented by the DDE motif of IN (Fig. 4). Various mechanisms by which
resistance is conferred by these mutations are likely complex and can
be proposed. A ﬁrst mechanism of resistance is based on a change in
an amino acid resulting in loss of the group/moiety to which the drug
is bound. In the model of Chen, Q148 and Y143 are located in the
hydrophobic pocket and are key residues making direct contact with
the benzyl moiety of RAL; mutation of these two residues can result in
loss of direct drug–enzyme contact, hence leading to resistance. E92 is
located at site 3 in the model and makes a polar interaction with RAL;
substitution of E92 to a glutamine disturbs this polar interaction,
leading to a reduced drug–enzyme contact and consequently to
resistance to RAL. Another mechanism of resistance is based on the
possible inﬂuence of IN mutations on the positions of the Mg2+ ions,
thereby interfering with the chelating function of the inhibitor. In the
model, the residue at position 155 makes contact with one of the Mg2+
ions. Therefore, mutation N155H may affect the coordination of the
Mg2+ ions within the architecture of the catalytic site and can sub-
sequently interfere with the chelating activity of RAL. Another
possibility is that N155H, which is in close proximity of the viral
DNA, may indirectly interrupt the binding of the inhibitor by altering
formation of the complex between IN and viral DNA. A high resolution
X-raydiffraction analysis of the crystal structure of the inhibitor-bound
IN complexwith DNA, which has remained elusive to date, would help
to test these hypotheses.Here we examined the association of selected mutations with the
activity of a panel of INIs, including second-generation INIs, and the
proﬁles of drug-resistant mutants in vitro. This research enabled us to
identify several mutational pathways leading to resistance against
ﬁrst-generation INIs like RAL, and illustrates the higher genetic barrier
to resistance development of second-generation INIs. A better
understanding of the mechanisms leading to INI resistance is needed
to optimize their use in HIV-infected patients and, enables the design
of new second-generation INIs.
Materials and methods
Abbreviations
EC50, inhibitor concentration required for 50% inhibition of HIV-1
replication in cell culture; CC50, cytotoxicity, inhibitor concentration
required for 50% inhibition of cell growth; HIV-1, human immuno-
deﬁciency virus type 1; HIV-1 (IIIB), wild-type HIV-1; IN, integrase;
INI, integrase inhibitor; LTR, long terminal repeat; HAART, highly
active antiretroviral therapy; SDM, site-directed mutant; EGFP,
enhanced green ﬂuorescent protein; MOI, multiplicity of infection;
CCID50, infectious dose required for infection of 50% of cell culture;
Table 3
Anti-HIV-1 (IIIB) activity and toxicity of a panel of INIs and of the control AZT.
CC50 (µM) EC50 (µM)
RAL N99 0.010
EVG 24 0.0033
PACA 71 0.0092
L-870,810 5 0.0087
PICA 4 0.075
MK-2048 12 0.0030
Cmpd G N8 0.0019
AZT N100 0.094
344 O. Goethals et al. / Virology 402 (2010) 338–346IVRS, in vitro resistance selection; RAM, resistance associated
mutation; RAL, raltegravir; EVG, elvitegravir; Cmpd G, Compound G.
Anti-viral compounds
Elvitegravir (EVG, GS-9137; Sato et al., 2006); Raltegravir (RAL,
MK-0518; Anker and Corales, 2008); L-870,810 (Hazuda et al., 2004);
PACA (a 3-Hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]
azepine-2-carboxylamide; Belyk et al.); PICA (a 9H-Pyrido[3,4-b]
indole-3-carboxamide; Kuki et al., 2005); Compound G (6R)-2-[(3-
chloro-4-ﬂuorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-
hydroxy-N,6-dimethyl-1,9-dioxo-yrazino[1′,2′:1,5]pyrrolo[2,3-d]pyr-
idazine-4-carboxamide (Cmpd G; Wai et al., 2007) and MK-2048
(Vacca et al., 2007); and the nucleoside reverse transcriptase inhibitor
Zidovudine (AZT; Horwitz et al., 1964) were obtained from commer-
cial suppliers or were synthesized in-house. Chemical structures are
shown in Fig. 5 and resulting activity and toxicity in Table 3.
Cells and viruses
The human T-lymphoblastoid cell line MT4 was kindly provided
by Dr. Naoki Yamamoto (National Institute of Infectious Diseases,
AIDS Research Center, Tokyo, Japan). The cell line was maintained in
RPMI 1640 medium supplemented with 10% heat-inactivated fetal
calf serum, 2 mM L-glutamine, 0.1% NaHCO3, antibiotics (0.02%
gentamycin, 0.8% G418), and stored in a humidiﬁed incubator with
a 5% CO2 atmosphere at 37 °C.
MT4–LTR–EGFP cells were obtained by transfecting MT4 cells with
a selectable construct encompassing the coding sequences for the
HIV-LTR as a promoter for the expression of enhanced green
ﬂuorescent protein (EGFP) and subsequent selection of permanently
transfected cells. MT4-CMV-EGFP cells were obtained by selection for
permanently transformed MT4 cells with an EGFP reporter gene
under control of the consecutive CMV promotor.
HIV-1 (IIIB) was provided by Dr. Guido van der Groen (Institute of
Tropical Medicine, Antwerp, Belgium). HIV-1 molecular clone pHXB2D
was provided by Centre for AIDS Reagents (ARP206; Brussels, Belgium).
Site-directed mutants (SDMs) of IN coding sequences were
constructed in the pUC19-5′HXB2D vector (XbaI–SalI fragment of
pHXB2D), containing the HIV-1 clone HXB2D IN coding sequence, by
using the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA) and high-performance liquid chromatography-puriﬁed
primers (Genset Oligos, La Jolla, CA). Plasmid sequences were
conﬁrmed by dideoxyribose sequencing.
Generation of the SDM virus stocks
MT4 cells were subcultured at a density of 250,000 cells/ml on the
day before transfection. Cells were pelleted and resuspended in
phosphate-buffered saline at a concentration of 3.1×106 cells/ml. A
0.8 ml portion (2.5×106 cells/ml) was used for each transfection.
Transfections were performedwith the Bio-Rad Gene pulser (Bio-Rad,
Hercules, CA) with 0.4 cm electrode cuvettes (Bio-Rad). Cells were
electroporated with 10 µg of SalI-linearized pUC19-3′HXB2D (SalI–XbaI fragment of pHXB2D) and 5 µg SalI-digested SDM at 250 µF and
300 V, followed by a 30 min incubation at room temperature. Next,
10 ml of fresh culture medium was added to the suspension of
transfected cells, which was then incubated at 37 °C in a humidiﬁed
atmosphere with 5% CO2. Cell cultures were monitored for the
appearance of cytopathic effect (CPE). At virus breakthrough (full
CPE), culture supernatant was typically harvested by centrifugation at
8 to 10 days after transfection and was stored at −80 °C for
subsequent drug susceptibility determination.
Antiviral assays
The antiviral activity of inhibitors was determined in a cell-based
HIV-1 replication assay in triplicate. Brieﬂy, MT4-LTR-EGFP cells
(400,000 cells/ml) were infected with HIV-1 (IIIB, HXB2D, selected
viruses, or SDM strains; multiplicity of infection MOI=0.0025) in the
presence or absence of inhibitor. After 3 days of incubation, the
inhibition of HIV replication was quantiﬁed by measuring EGFP
ﬂuorescence, and expressed as EC50 values. The cytotoxicity of
inhibitors was determined in parallel on mock-infected MT4-CMV-
EGFP cells (150,000 cells/ml) cultured in the presence or absence of
test compound concentrations (data not shown). After three days of
incubation, inhibition of cell proliferation was quantiﬁed by measur-
ing the EGFP ﬂuorescence, and expressed as CC50 values (cytotoxicity,
50% inhibitory concentration of cell growth).
Genotyping
Viral RNA was extracted from culture supernatant or virus stock
using a NucliSens easyMAG apparatus (bioMérieux, Marcy l' Etoile,
France), a high-throughput automated nucleic acid extraction system.
cDNAencoding reverse transcriptase and INwasgeneratedwith Expand
Reverse Transcriptase (Roche Diagnostics, Basel, Switzerland), followed
by ampliﬁcation of the IN region by nested PCR (1456 bp). PCRproducts
were genotyped by automated population-based full-sequence analysis
(ABI PRISM BigDye Terminator cycle sequencing; Applied Biosystems,
Foster City, CA). Sequencing results were reported as amino acid
changes compared with the HIV-1 (IIIB) or (HXB2D) wild-type
reference sequence. Mutations present in more than 25% of the total
virus population were detected as a mixture with the wild type virus.
Automated IVRS experiments in 96-well plates (Goethals et al., 2008)
In vitro selection was performed in 96-well plates, with each row
representing a separate IVRS experiment. In contrast with the classical
IVRS experiment, where the compound concentration is only increased
at viral breakthrough, this method uses a protocol where the virus is
challenged with an increased compound concentration at each passage.
HIV-1 IIIBwasusedas starting strain for the IVRSwithRAL,whereasHIV-1
HXB2D was used as starting strain for IVRS with MK-2048 and Cmpd G.
Replication kinetics of recombinant viruses
MT4 cells (120,000 cells) were infected with HIV-1 (HXB2D or
recombinant viruses; MOI of 0.0001) in the absence of inhibitor
(Fig. 3). Every day, cells were examined for the appearance of HIV-1-
induced CPE. In addition, aliquots of cell-free supernatants were taken
for determination of viral p24 levels (HIV-1 p24 enzyme-linked
immunosorbent assay, Perkin Elmer, Waltham, MA).
Molecular modeling
Compounds were docked, using glide (ref: Glide, version 5.0,
Schrödinger, LLC, New York, NY, 2008.), in a model provided by Chen
et al. (2008), who developed a model of HIV-1 IN bound to the viral
DNA, therebymimicking the strand transfer complex. In this model an
345O. Goethals et al. / Virology 402 (2010) 338–346X-ray structure of the IN CCD is combined with viral DNA, which is
based on the crystal structure of DNA-bound Tn5, a structural
homologue of HIV-1 IN. The ﬂexible loop (residues 140–152) was
computationally constructed in the presence of viral DNA, since the
biologically relevant conformation of this loop may be dependent on
the presence of bound DNA.
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